CurrentAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity criteria and coding guidance for treatments of primary hyperhidrosis (iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy) for members/enrollees covered by the health plan.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeCriteria revisionsthresholds addedcounseling requirement added

Effective Date

Last ReviewOct 13, 2025

Next Review Date

Key ActionObtain prior authorization and document trials of conservative management (including adherent use of prescription aluminum chloride) before iontophoresis or surgery.

SourceLink

POLICY UPDATE CHANGES

Updated criteria I.E.3. by removing pregnancy improvement language and added epilepsy to contraindications.

Updated Criteria II.B. to require resting heart rate > 55 beats per minute for ETS.

Removed six-month time-frame requirement for trial of conservative management and removed certain prior pharmacotherapy requirement wording.

Added counseling on procedural risks as a required criterion for ETS.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAmbetter NevadaPolicy CP.MP.62

Hyperhidrosis Treatments

Customize your policy alerts

Sign up for Ambetter Nevada Policy CP.MP.62 alerts

Get alerted when Policy CP.MP.62 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerAmbetter Nevada

PolicyHyperhidrosis Treatments

Policy CodePolicy CP.MP.62

Change TypeCriteria revisionsthresholds addedcounseling requirement added

Effective Date

Last ReviewOct 13, 2025

Next Review Date

Key ActionObtain prior authorization and document trials of conservative management (including adherent use of prescription aluminum chloride) before iontophoresis or surgery.

SourceLink

POLICY UPDATE CHANGES

Updated criteria I.E.3. by removing pregnancy improvement language and added epilepsy to contraindications.

Updated Criteria II.B. to require resting heart rate > 55 beats per minute for ETS.

Removed six-month time-frame requirement for trial of conservative management and removed certain prior pharmacotherapy requirement wording.

Added counseling on procedural risks as a required criterion for ETS.

Coverage Criteria for Hyperhidrosis Treatments

Iontophoresis (including Drionic device)

Covered when ALL of the following are met:

Iontophoresis medical necessity criteria: A. Diagnosis of primary hyperhidrosis; B. Development of medical complications (e.g., skin maceration with secondary skin infections) or significant constant disruption of professional and/or social life due to excessive sweating; C. Failed a trial of conservative management including adherent application of aluminum chloride hexahydrate (prescription Drysol) or topical agents resulted in a severe rash; D. Has none of the following contraindications: 1. Cardiac pacemaker; 2. Cardiac arrhythmias; 3. Pregnancy; 4. Metal implants, depending on size and position; 5. Epilepsy.

Surgical excision of axillary sweat glands

Covered when ALL of the following are met:

Excision criteria: A. Meets all of the iontophoresis criteria in I.A through I.D; B. Has persistent and severe primary hyperhidrosis; C. Has failed one of the following: 1. Iontophoresis; 2. Trial of botulinum toxin.

Endoscopic thoracic sympathectomy (ETS) for palmar or palmar and axillary hyperhidrosis

Covered when ALL of the following are met:

ETS criteria: A. Meets all of the iontophoresis criteria in I.A through I.D; B. Member/enrollee has a resting heart rate > 55 beats per minute; C. Hyperhidrosis symptoms started at an early age (usually <16 years), and surgery is requested for a young member/enrollee (usually <25 years of age); D. Body mass index < 28; E. Reports no sweating during sleep; F. Member/enrollee has no significant comorbidities; G. Member/enrollee has persistent and severe primary hyperhidrosis; H. Member/enrollee has failed one of the following: 1. Iontophoresis; 2. Trial of botulinum toxin for predominantly axillary hyperhidrosis; I. Member/enrollee has been counseled on risks of procedure.

Other therapies for axillary hyperhidrosis — including microwave energy systems (e.g., miraDry), diathermy, or liposuction performed as the sole method of removing axillary sweat glands — are not supported by this policy because the published peer‑reviewed literature provides insufficient evidence to demonstrate their safety and efficacy. The policy explicitly states there is insufficient evidence to support all other treatments for hyperhidrosis, including, but not limited to, microwave therapy or liposuction as sole methods of treatment.

Device labeling and external guidance recognize the miraDry System as an FDA‑cleared device for primary axillary hyperhidrosis, but independent assessments (for example, NICE) conclude current evidence is inadequate in quantity and quality and recommend use only with special arrangements for governance, consent, audit, or research — reinforcing the policy stance that evidence is inadequate to support routine coverage.

Use of microwave energy, diathermy, or liposuction as the sole treatment for axillary hyperhidrosis is specifically not supported by this policy due to inadequate evidence in the published literature. When these modalities are proposed, documentation must demonstrate how the proposed approach meets policy criteria; absent such evidence, coverage for these methods alone should not be authorized.

Although some devices (for example, miraDry) have FDA clearance for primary axillary hyperhidrosis, external guidance and the policy both indicate that the current evidence base is insufficient to endorse these therapies as stand‑alone, routinely covered treatments.

Coding and Key Clinical Thresholds

CPT Codes referencedCPT

11450	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with simple or intermediate repair.
11451	Excision of skin and subcutaneous tissue for hidradenitis, axillary; with complex repair.
15877	Suction assisted lipectomy; trunk.
15878	Suction assisted lipectomy; upper extremity.
32664	Thoracoscopy, surgical; with thoracic sympathectomy.
97024	Application of a modality to 1 or more areas; diathermy (eg, microwave).
97033	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes.

Resting heart rate for ETS

Clinical thresholdResting heart rate > 55 beats per minute is required for ETS eligibility.

Context in ETS criteriaThis numeric threshold is listed as Criterion II.B in the ETS coverage criteria.

Documentation requirementProvider must document resting heart rate in the medical record to support ETS medical necessity.

Body mass index for ETS

Clinical thresholdBody mass index (BMI) < 28 is required for ETS eligibility.

Context in ETS criteriaThis BMI threshold appears as Criterion II.D in the ETS coverage criteria.

Provider Actions, Prior Authorization, and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for all referenced CPT codes related to iontophoresis, surgical excision of axillary sweat glands, and endoscopic thoracic sympathectomy. Submit prior authorization requests with supporting clinical documentation before performing or billing these services.

Affected CPT codes include, but may not be limited to: 32664 (thoracic sympathectomy); 11450, 11451 (excision of axillary skin/subcutaneous tissue); 97033 (iontophoresis); 15877, 15878, 97024 (procedures/modalities referenced)

Documentation Required

Required Documentation to Support Medical Necessity

Required Documentation to Support Medical Necessity: Provide documentation in the prior authorization and medical record that clearly supports the diagnosis of primary hyperhidrosis and the medical necessity of the requested treatment.

Diagnosis of primary hyperhidrosis (location: palmar, plantar, axillary, or palmar/axillary as applicable)

Background on Primary Focal Hyperhidrosis

Primary focal hyperhidrosis is an idiopathic condition characterized by visible, excessive focal sweating — most commonly affecting the axillae, palms, and soles — that often begins at a young age and can cause substantial social or occupational impairment. The policy treats ETS as an invasive, last‑resort surgical intervention reserved for persistent, severe primary hyperhidrosis after conservative therapies (including iontophoresis or botulinum toxin where indicated) have failed.

Because ETS carries risks such as compensatory sweating and other potential complications, the policy requires stringent selection criteria (including physiological thresholds and counseling on procedural risks) before considering endoscopic thoracic sympathectomy for palmar or palmar/axillary hyperhidrosis.

Key Definitions

Primary focal hyperhidrosis — definition

DefinitionPrimary focal hyperhidrosis is visible, excessive focal sweating of at least six months' duration without apparent cause.

Common locationsMost common sites include axillae (underarms), palms (hands), and soles (feet).

EtiologyIdiopathic sympathetic hyperactivity in selected areas, not associated with underlying disease processes.

Endoscopic thoracic sympathectomy (ETS) — definition and risks

Definition of ETSEndoscopic thoracic sympathectomy (ETS) is an invasive surgical interruption of the upper thoracic sympathetic chain performed for palmar or palmar/axillary hyperhidrosis.

CharacterizationConsidered a last-resort therapy reserved for refractory cases due to risks such as serious, irreversible compensatory sweating and other potential complications (e.g., extreme hypotension, arrhythmia, heat intolerance).